Curium Pharma

Sébastien Delannoy, Sales Manager, Benelux, says the best part of working at Curium is seeing how rapidly nuclear medicine is advancing as well as being part of a team that goes above and beyond to support healthcare professionals and patients.    His advice for anyone considering a career at Curium? "Don't hesitate – it's a once-in-a-lifetime career opportunity!"    Learn more: https://lnkd.in/dG_PztiU    #LifeAtCurium #CuriumCareers #TeamCurium #MovingLifeForward 

Curium reintroduces Thallous Chloride Tl 201 Injection in the U.S. to support high-stakes cardiac imaging needs. Collaborating with nuclear cardiology leaders, Curium is restoring access to a radiopharmaceutical used in nuclear cardiology after production ceased in 2022. Renewed availability can help diversify diagnostic pathways for select patients undergoing myocardial perfusion evaluation.  “For select patients, Thallous Chloride Tl 201 Injection can support timely, actionable imaging when operational flexibility matters, helping to reduce uncertainty so care teams can make confident, time-sensitive decisions and move quicky to the most appropriate next steps” said Andrew J. Einstein, MD, PhD, Director of Nuclear Cardiology, Cardiac CT and Cardiac MRI at NewYork-Presbyterian/Columbia University Irving Medical Center. This is an important milestone for Curium and crucially the patients we serve. Read full press release here: https://lnkd.in/eJPX6-sX Indications & Usage Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of non-reversible defects (myocardial infarction) or of reversible defects (myocardial ischemia) when used in conjunction with stress.   IMPORTANT SAFETY INFORMATION Warnings and Precautions Radiation Risk: Thallous Chloride Tl 201 contributes to the overall long-term cumulative radiation exposure which is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration.   Please click here for additional Important Safety Information: https://lnkd.in/ewSWZbRi Please click here for full Prescribing Information: https://lnkd.in/erCiY-UW #Curium #NuclearMedicine #NuclearCardiology #Thallium201 #MedicalImaging #PatientCare

For decades, Thallous Chloride Tl 201 Injection has played an important role in myocardial perfusion imaging, helping clinicians assess heart muscle viability and support evidence-based treatment decisions. With its reintroduction, more patients can once again access myocardial viability testing, particularly those who may not be candidates for MRI or who do not have access to PET imaging. At Curium, we're proud to help expand access to trusted nuclear medicine solutions that support better patient care in the U.S. Indications & Usage Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of non-reversible defects (myocardial infarction) or of reversible defects (myocardial ischemia) when used in conjunction with stress. IMPORTANT SAFETY INFORMATION Warnings and Precautions   Radiation Risk: Thallous Chloride Tl 201 contributes to the overall long-term cumulative radiation exposure which is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration.   Please click here for additional Important Safety Information: https://lnkd.in/ewSWZbRi Please click here for full Prescribing Information: https://lnkd.in/erCiY-UW #Curium #NuclearMedicine #NuclearCardiology #Thallium201 #MyocardialPerfusion #PatientCare

Drake Steffenauer is a Business Administration student at the University of Missouri-Columbia and is currently doing an internship with our Legal and Quality teams.    Drake describes his role as rewarding, challenging, and valuable, highlighting the opportunity to grow, build confidence, and develop new skills in a supportive environment.    Thank you for being so committed and open to learning and growing with us.    Learn more about Curium careers: https://lnkd.in/dG_PztiU   #InternSpotlight #LifeAtCurium #EarlyCareers #TeamCurium 

Thallous Chloride Tl 201 Injection is coming back to the U.S. market! It’s a great story. Andrew J. Einstein, MD, PhD, Director of Nuclear Cardiology, Cardiac CT and Cardiac MRI at NewYork-Presbyterian/Columbia University Irving Medical Center, tells us how important it is in helping clinicians make informed treatment decisions while supporting timely cardiac imaging. We like to collaborate at Curium, and we're committed to providing nuclear medicine solutions that help healthcare professionals deliver confident diagnoses and improve patient care. Together with nuclear cardiology leaders, we have re-started production. Indications & Usage Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of non-reversible defects (myocardial infarction) or of reversible defects (myocardial ischemia) when used in conjunction with stress. IMPORTANT SAFETY INFORMATION Warnings and Precautions Radiation Risk: Thallous Chloride Tl 201 contributes to the overall long-term cumulative radiation exposure which is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration. Please click here for additional Important Safety Information: https://lnkd.in/ewSWZbRi Please click here for full Prescribing Information: https://lnkd.in/erCiY-UW #Curium #NuclearMedicine #NuclearCardiology #Thallium201 #Cardiology #PatientCare

More than 250 colleagues and their families competed in Curium’s annual triathlon in St Louis, MO this year. It’s growing every year! Our core values featured throughout the day with “never giving up” outshining the others with everyone doing incredibly well given the extraordinary heat. It was another unforgettable event with high energy and great team spirit. Highlights video below. #TeamCurium #LifeAtCurium #Curium #MovingLifeForward

Every cancer journey is different.  The commonality is that it impacts more than the patient – it affects the patient's family and friends.    In this powerful video, Michael and his family share their experience of living with advanced prostate cancer and how radioligand therapy brought renewed hope when a new treatment option was needed.    At Curium, we're committed to advancing precision nuclear medicine to help make a meaningful difference for patients and their families.    Thank you, Michael, for sharing your inspiring story.    #Curium #RadioligandTherapy #NuclearMedicine #ProstateCancer #PatientStories #Oncology 

Curium’s UK & Ireland team win at the Swansea 70.3 Triathlon! 🏊🚴🏃    We're proud to share that our Curium Prostate 2 relay team featuring Simon Martin, kathryn thomas, and Oliver Neil, finished in 1st place! Together with our NHS colleagues, our two relay teams took on the challenge to raise funds for CHAPS (https://chaps-uk.org/) , supporting a national prostate cancer screening programme.    A huge thank you to everyone who has supported us so far. There's still time to donate – every contribution helps support this important cause and raises awareness of prostate cancer.    https://lnkd.in/eGVRd7Em   #Triathlon #TeamCurium #ProstateCancer #ProstateCancerAwareness #EarlyDetection #CancerAwareness #Fundraising #Healthcare #NHS #MakingADifference #Community #Teamwork 

For Oliver Neil, every day at Curium is driven by one purpose: improving patients’ lives    As Site Lead in Oxford, his work is very varied and ranges from the launch of PYLCLARI® in the UK to helping deliver an urgent tracer for a newborn baby.  His work reflects the real impact our teams make every day for patients.    "Behind every dose is a person depending on us. That's something I carry with me every day."    Thank you, Oliver, for your dedication and for living Curium's commitment to patients, quality, and innovation.    Learn more about Curium careers: https://lnkd.in/dG_PztiU   #EmployeeSpotlight #LifeAtCurium #PatientCare #NuclearMedicine #TeamCurium 

We're looking forward to the 45th Annual Meeting of the Bavarian Society of Nuclear Medicine (BGN) this weekend in Garmisch-Partenkirchen.   Curium is pleased to host a symposium on Saturday, 11 July, bringing together leading experts to discuss how clinical evidence is advancing the implementation of radioligand therapy in everyday practice.   We look forward to connecting with colleagues, exchanging ideas, and contributing to the future of nuclear medicine. See you at BGN 2026!   Prof. Marcus Unterrainer, PD Dr. med. Isabel Rauscher, Prof. Wolfgang Weber   #BGN2026 #NuclearMedicine #RadioligandTherapy #Theranostics #Curium